804TiP CaboPoint: A phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)

od Albiges, L., Schmidinger, M., Taguieva-Pioger, N., Perol, D., Gruenwald, V.
Izdano u Ann Oncol (2020)

P14.127 From next generation sequencing and comparative genomic hybridization to personalised medicine for adult primary brain tumors: the profiler trial

od Bonneville-levard, A, Frappaz, D, Pissaloux, D, Wang, Q, Perol, D, Blay, J, Meyronet, D
Izdano u Neuro Oncol (2019)

The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis

od Frappaz, D, Perol, D, Michon, J, Berger, C, Coze, C, Bernard, J L, Zucker, J M, Philip, T
Izdano 2002

OS4.1 MEVITEM: A European, randomized, open-label, Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or ref...

od Frappaz, D, Barritault, M, Montané, L, Laigle-Donadey, F, Chinot, O, Le Rhun, E, Bonneville-Levard, A, Meyronnet, D, Garin, G, Pérol, D
Izdano u Neuro Oncol (2019)

Cancer-related fatigue management: evaluation of a patient education program with a large-scale randomised controlled trial, the PEPs fatigue study

od Bourmaud, A, Anota, A, Moncharmont, C, Tinquaut, F, Oriol, M, Trillet-Lenoir, V, Bajard, A, Parnalland, S, Rotonda, C, Bonnetain, F, Pérol, D, Chauvin, F
Izdano u Br J Cancer (2017)

Design of a randomised controlled trial of adapted physical activity during adjuvant treatment for localised breast cancer: the PASAPAS feasibility study

od Touillaud, M, Foucaut, A-M, Berthouze, S E, Reynes, E, Kempf-Lépine, A-S, Carretier, J, Pérol, D, Guillemaut, S, Chabaud, S, Bourne-Branchu, V, Perrier, L, Trédan, O, Fervers, B, Bachmann, P
Izdano 2013

Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay

od Verronèse, E., Delgado, A., Valladeau-Guilemond, J., Garin, G., Guillemaut, S., Tredan, O., Ray-Coquard, I., Bachelot, T., N'Kodia, A., Bardin-Dit-Courageot, C., Rigal, C., Pérol, D., Caux, C., Ménétrier-Caux, C.
Izdano u Oncoimmunology (2015)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis

od Dufresne, A, Bertucci, F, Penel, N, Le Cesne, A, Bui, B, Tubiana-Hulin, M, Ray-Coquard, I, Cupissol, D, Chevreau, C, Perol, D, Goncalves, A, Jimenez, M, Bringuier, P P, Blay, J Y
Izdano 2010

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort

od Grinda, T., Antoine, A., Jacot, W., Blaye, C., Cottu, P.-H., Diéras, V., Dalenc, F., Gonçalves, A., Debled, M., Patsouris, A., Mouret-Reynier, M.-A., Mailliez, A., Clatot, F., Levy, C., Ferrero, J.-M., Desmoulins, I., Uwer, L., Petit, T., Jouannaud, C., Lacroix-Triki, M., Deluche, E., Robain, M., Courtinard, C., Bachelot, T., Brain, E., Pérol, D., Delaloge, S.
Izdano u ESMO Open (2021)

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

od Blay, J.Y., Boucher, S., Le Vu, B., Cropet, C., Chabaud, S., Perol, D., Barranger, E., Campone, M., Conroy, T., Coutant, C., De Crevoisier, R., Debreuve-Theresette, A., Delord, J.P., Fumoleau, P., Gentil, J., Gomez, F., Guerin, O., Jaffré, A., Lartigau, E., Lemoine, C., Mahe, M.A., Mahon, F.X., Mathieu-Daude, H., Merrouche, Y., Penault-Llorca, F., Pivot, X., Soria, J.C., Thomas, G., Vera, P., Vermeulin, T., Viens, P., Ychou, M., Beaupere, S.
Izdano u ESMO Open (2021)

Surgery in reference centers improves survival of sarcoma patients: a nationwide study

od Blay, J -Y, Honoré, C, Stoeckle, E, Meeus, P, Jafari, M, Gouin, F, Anract, P, Ferron, G, Rochwerger, A, Ropars, M, Carrere, S, Marchal, F, Sirveaux, F, Di Marco, A, Le Nail, L R, Guiramand, J, Vaz, G, Machiavello, J -C, Marco, O, Causeret, S, Gimbergues, P, Fiorenza, F, Chaigneau, L, Guillemin, F, Guilloit, J -M, Dujardin, F, Spano, J -P, Ruzic, J -C, Michot, A, Soibinet, P, Bompas, E, Chevreau, C, Duffaud, F, Rios, M, Perrin, C, Firmin, N, Bertucci, F, Le Pechoux, C, Le Loarer, F, Collard, O, Karanian-Philippe, M, Brahmi, M, Dufresne, A, Dupré, A, Ducimetière, F, Giraud, A, Pérol, D, Toulmonde, M, Ray-Coquard, I, Italiano, A, Le Cesne, A, Penel, N, Bonvalot, S
Izdano u Ann Oncol (2019)

Surgery in reference centers improves survival of sarcoma patients: a nationwide study

od Blay, J -Y, Honoré, C, Stoeckle, E, Meeus, P, Jafari, M, Gouin, F, Anract, P, Ferron, G, Rochwerger, A, Ropars, M, Carrere, S, Marchal, F, Sirveaux, F, Di Marco, A, Le Nail, L R, Guiramand, J, Vaz, G, Machiavello, J -C, Marco, O, Causeret, S, Gimbergues, P, Fiorenza, F, Chaigneau, L, Guillemin, F, Guilloit, J -M, Dujardin, F, Spano, J -P, Ruzic, J -C, Michot, A, Soibinet, P, Bompas, E, Chevreau, C, Duffaud, F, Rios, M, Perrin, C, Firmin, N, Bertucci, F, Le Pechoux, C, Le Loarer, F, Collard, O, Karanian-Philippe, M, Brahmi, M, Dufresne, A, Dupré, A, Ducimetière, F, Giraud, A, Pérol, D, Toulmonde, M, Ray-Coquard, I, Italiano, A, Le Cesne, A, Penel, N, Bonvalot, S
Izdano u Ann Oncol (2019)

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

od Heudel, P., Chabaud, S., Perol, D., Flechon, A., Fayette, J., Combemale, P., Tredan, O., Desseigne, F., de la Fouchardiere, C., Boyle, H., Perol, M., Bachelot, T., Cassier, P., Avrillon, V., Terret, C., Michallet, A.-S., Neidhardt-Berard, E.-M., Nicolas-Virelizier, E., Dufresne, A., Belhabri, A., Brahmi, M., Lebras, L., Nicolini, F., Sarabi, M., Rey, P., Bonneville-Levard, A., Rochefort, P., Provensal, A.-M., Eberst, L., Assaad, S., Swalduz, A., Saintigny, P., Toussaint, P., Guillermin, Y., Castets, M., Coutzac, C., Meeus, P., Dupré, A., Durand, T., Crochet, H., Fervers, B., Gomez, F., Rivoire, M., Gregoire, V., Claude, L., Chassagne-Clement, C., Pilleul, F., Mognetti, T., Russias, B., Soubirou, J.-L., Lasset, C., Chvetzoff, G., Mehlen, P., Beaupère, S., Zrounba, P., Ray-Coquard, I., Blay, J.-Y.
Izdano u ESMO Open (2021)